<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02230254</url>
  </required_header>
  <id_info>
    <org_study_id>S2323</org_study_id>
    <nct_id>NCT02230254</nct_id>
  </id_info>
  <brief_title>PE PREMIER CHINA CLINICAL TRIAL</brief_title>
  <official_title>PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM
      Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of
      Atherosclerotic Lesion(s)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate clinical and peri-procedural angiographic outcomes for the Promus PREMIERTM
      Everolimus-Eluting Platinum Chromium Coronary Stent System in the treatment of subjects with
      atherosclerotic lesion(s) ≤34 mm in length (by visual estimate) in native coronary arteries
      ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2014</start_date>
  <completion_date type="Actual">July 31, 2015</completion_date>
  <primary_completion_date type="Actual">June 22, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day</time_frame>
    <description>Technical success rate, defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of &lt;30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6month and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI, Q-wave and non-Q-wave) rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or MI rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death or MI rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death/MI/TVR rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate (by Academic Research Consortium [ARC] definitions)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical procedural success rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment percent diameter stenosis (%DS)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment minimum lumen diameter (MLD)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute gain</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
    <description>as measured by angiographic core lab, change from baseline for target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal stent deformation (LSD) rate</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>PROMUS POREMIER stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm treatment group receiving interventional PROMUS PRIMIER study stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention PROMUS PREMIER</intervention_name>
    <description>PROMUS PREMIER</description>
    <arm_group_label>PROMUS POREMIER stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Inclusion (CI) Criteria

        CI1. Subject must be at least 18 -75 years of age

        CI2. Subject (or legal guardian) understands the trial requirements and the treatment
        procedures and provides written informed consent before any trial-specific tests or
        procedures are performed

        CI3. Subject is eligible for percutaneous coronary intervention (PCI)

        CI4. Subject has symptomatic coronary artery disease with objective evidence of ischemia or
        silent ischemia

        CI5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG)

        CI6. Subject is willing to comply with all protocol-required follow-up evaluation

        CI7. Subject has a left ventricular ejection fraction (LVEF) &gt;30% as measured within 60
        days prior to enrollment

          -  Angiographic Inclusion (AI) Criteria (visual estimate)

        AI1. Target lesion(s) must be located in a native coronary artery with a visually estimated
        reference vessel diameter (RVD) ≥2.25 mm and ≤4.0 mm

        AI2. Target lesion(s) length must be ≤34 mm ( Target lesion(s) length must be ≤28 mm for
        reference vessel diameter (RVD) = 2.25 mm Target lesion(s)) (by visual estimate)

        AI3. Target lesion(s) must have visually estimated stenosis ≥50% and &lt;100% with
        thrombolysis in Myocardial Infarction (TIMI) flow &gt;1 and one of the following (stenosis
        ≥70%, abnormal fractional flow reserve (FFR), abnormal stress test or imaging stress test,
        or elevated biomarkers) prior to procedure

        AI4. Coronary anatomy is likely to allow delivery of a study device to the target
        lesions(s)

        AI5. The first lesion treated must be successfully pre-dilated/pretreated Note: Successful
        pre-dilatation/pretreatment refers to dilatation with a balloon catheter of appropriate
        length and diameter, or pretreatment with/or rotational coronary atherectomy, or
        cutting/scoring balloon with no greater than 50% residual stenosis and no dissection
        greater than National Heart, Lung, Blood Institute (NHLBI) type C.

        Exclusion Criteria:

          -  Clinical Exclusion (CE) Criteria

        CE1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
        Acute MI (include STEMI and Non- STEMI ) within 1 week

        CE2. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or
        mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable
        angina

        CE3. Subject has received an organ transplant or is on a waiting list for an organ
        transplant

        CE4. Subject is receiving or scheduled to receive chemotherapy within 30 days before or
        after the index procedure

        CE5. Planned PCI (including staged procedures) or CABG after the index procedure

        CE6. Subject previously treated at any time with intravascular brachytherapy

        CE7. Subject has a known allergy to contrast (that cannot be adequately pre-medicated)
        and/or the trial stent system or protocol-required concomitant medications (e.g., platinum,
        platinum-chromium alloy, stainless steel, everolimus or structurally related compounds,
        polymer or individual components, Clopidogrel , or aspirin)

        CE8. Subject has one of the following (as assessed prior to the index procedure):

          -  Other serious medical illness (e.g., cancer, congestive heart failure) with estimated
             life expectancy of less than 12 months

          -  Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)

          -  Planned procedure that may cause non-compliance with the protocol or confound data
             interpretation

        CE9. Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin,
        coumadin) for indications other than acute coronary syndrome

        CE10. Subject with out of range complete blood count (CBC) values that are determined by
        the study physician to be clinically significant.

        CE11. Subject has documented or suspected liver disease, including laboratory evidence of
        hepatitis

        CE12. Subject is on dialysis or has baseline serum creatinine level &gt;2.0 mg/dL (177µmol/L)

        CE13. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
        transfusions

        CE14. Subject has had a history of cerebrovascular accident (CVA) or transient ischemic
        attack (TIA) within the past 6 months

        CE15. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding

        CE16. Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the
        time of the index procedure

        CE17. Subject is participating in another investigational drug or device clinical trial
        that has not reached its primary endpoint

        CE18. Subject intends to participate in another investigational drug or device clinical
        trial within 12 months after the index procedure

        CE19. Subject with known intention to procreate within 12 months after the index procedure
        (women of child-bearing potential who are sexually active must agree to use a reliable
        method of contraception from the time of screening through 12 months after the index
        procedure)

        CE20. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed
        within 7 days prior to the index procedure in women of child-bearing potential)

        CE21.Target vessel has been treated with any type of PCI (e.g., balloon angioplasty, stent,
        cutting balloon, atherectomy) within 12 months prior to the index procedure

          -  Angiographic Exclusion (AE) Criteria (visual estimate)

        AE1. Planned treatment of more than 3 lesions.

        AE2. Planned treatment of lesions in more than 2 major epicardial vessels

        AE3. Planned treatment of a single lesion with more than 1 stent

        AE4. Subject has 2 target lesions in the same vessel that are separated by less than 20 mm
        (by visual estimate)

        AE5. Target lesion(s) is located in the left main

        AE6. Target lesion(s) is located within 3 mm of the origin of the left anterior descending
        (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.

        AE7. Target lesion(s) is located within a saphenous vein graft or an arterial graft

        AE8. Target lesion(s) will be accessed via a saphenous vein graft or arterial graft

        AE9. Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide
        wire crossing

        AE10. Target lesion(s) treated during the index procedure that involves a complex
        bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)

        AE11. Target lesion(s) is restenotic from a previous stent implantation or study stent
        would overlap with a previous stent

        AE12. Subject has unprotected left main coronary artery disease (&gt;50% diameter stenosis)

        AE13. Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent,
        cutting balloon atherectomy) within 24 hours prior to the index procedure

        AE14. Thrombus, or possible thrombus, present in the target vessel (by visual estimate)

        AE15. Excessive tortuosity proximal to or within the lesion

        AE16. Excessive angulation proximal to or within the lesion

        AE17. Target lesion and/or the target vessel proximal to the target lesion is moderately to
        severely calcified by visual estimate

        AE18. Involves a side branch ≥2.0 mm in diameter by visual estimate or a side branch &lt;2.0
        mm in diameter by visual estimate which requires treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian'an Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd affiliated hospital of Zhejiang University College of Medicine</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

